Skip to main content

Table 3 Worm distribution in the hepatic and portomesenteric vessels of S. mansoni-infected treated mice

From: A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

Dose (mg/kg)

Animal group

Total no. of worms

Total no. of male worms

Total no. of female worms

Total no. of hepatic worms

Total no. of portomesenteric worms

Control

21.00 ± 0.59

12.44 ± 1.6

8.56 ± 1.0

5.33 ± 1.14

15.66 ± 1.98

62.5

M-PZQ

10.17 ± 0.4

(51.59)*

6.33 ± 1.0

(49.09)*

3.83 ± 0.7

(55.22)*

4.66 ± 0.8

5.5 ± 0.62*

SLN-PZQ

2.83 ± 0.7

(86.51)*

2.67 ± 0.7

(78.56)*

0.17 ± 0.1

(98.05)*

1.00 ± 0.26*

1.83 ± 0.60*

125

M-PZQ

5.83 ± 0.7

(72.22)*

3.83 ± 1.0

(69.19)*

1.33 ± 0.2

(84.42)*

2.83 ± 0.98*

2.33 ± 0.76*

SLN-PZQ

1.17 ± 0.4

(94.44)*

0.83 ± 0.3

(92.50)*

0.33 ± 0.2

(95.33)*

0.33 ± 0.21*$

0.83 ± 0.98*

250

M-PZQ

2.29 ± 0.1

(89.10)*

2.0 ± 0.2

(83.92)*

0.29 ± 0.1

(96.66)*

0.57 ± 0.4*

0.57 ± 0.20*

SLN-PZQ

0.83 ± 0.3

(96.05)*

0.67 ± 0.2

(94.64)*

0.17 ± 0.1

(98.05)*

0.33 ± 0.5*

0.33 ± 0.20*

500

M-PZQ

1.43 ± 0.2

(93.19)*

0.86 ± 0.3

(93.11)*

0.57 ± 0.2

(93.32)*

1.17 ± 0.38*

0.29 ± 0.49*

SLN-PZQ

0.50 ± 0.3

(97.62)*

0.33 ± 0.3

(97.32)*

0.33 ± 0.2

(98.05)*

0.5 ± 0.34*

0.00 ± 0.00*

1000

M-PZQ

0.75 ± 0.3

(96.43)*

0.63 ± 0.3

(94.98)*

0.13 ± 0.1

(98.54)*

0.75 ± 0.31*

0.00 ± 0.00*

SLN-PZQ

0.33 ± 0.2

(98.43)*

0.33 ± 0.2

(97.32)*

0.00 ± 0.0

(100.0)*

0.17 ± 0.16*

0.16 ± 0.16*

  1. Notes: Data are presented as the means ± SEM. n = 6–8 mice per group. Mice were sacrificed 14 days after treatment. Number in parentheses represents the percentage worm reduction versus the infected untreated control. Percentage of worm reduction = (mean number of worms in control group - mean number of worms in treated group)/mean number in control group × 100
  2. * Significant differences of SLN-PZQ or M-PZQ versus parallel infected untreated control at P < 0.05
  3. Significant differences of SLN-PZQ versus parallel values of M-PZQ at P < 0.05
  4. Abbreviations: SLN-PZQ, solid lipid nanoparticle praziquantel; M-PZQ, market praziquantel